Pharmacological modulation of prostaglandin E2 (PGE2) EP receptors improves cardiomyocyte function under hyperglycemic conditions

Pharmacological modulation of prostaglandin E2 (PGE2) EP receptors improves cardiomyocyte function under hyperglycemic conditions

Type 2 diabetes (T2D) affects >30 million Americans and nearly 70% of individuals with T2D will die from cardiovascular disease (CVD). Circulating levels of the inflammatory signaling lipid, prostaglandin E2 (PGE2), are elevated in the setting of obesity and T2D and are associated with decreased...

Full description

Bibliographic Details
Main Authors: Andrei, S.R (Author), Bosma, K.J (Author), Burkett, J.B (Author), Damron, D.S (Author), Dunn, J.C (Author), Gannon, M. (Author), Ghosh, M. (Author), Hatzopoulos, A.K (Author), Ricciardi, V.F (Author), Zhong, L. (Author)
Format: Article
Language:English
Published: American Physiological Society 2022
Subjects:
animal
Animals
cardiac muscle cell
contractility
Diabetes Mellitus, Type 2
diabetic cardiomyopathy
Dinoprostone
ejection fraction
human
Humans
hyperglycemia
Hyperglycemia
Mice
mouse
Myocytes, Cardiac
non insulin dependent diabetes mellitus
prostaglandin E receptor 3
prostaglandin E receptor 4
prostaglandin E2
prostaglandin receptor
Receptors, Prostaglandin E, EP3 Subtype
Receptors, Prostaglandin E, EP4 Subtype
Type 2 diabetes
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items